Ocular Therapeutix (OCUL) Stock Price, News & Analysis

Company Overview

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Key Stats

• Today's Range: $7.08 to $7.39
• 50-Day Range: $6.02 to $8.80
• 52-Week Range: $4.79 to $11.78
• Volume: 1.64 million shs
• Average Volume: 1.40 million shs
• Market Capitalization: $1.15 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.25
• Consensus Rating: Moderate Buy

Ocular Therapeutix Stock Analysis - MarketRank™

Ocular Therapeutix scored higher than 83% of companies evaluated by MarketBeat, and ranked 397th out of 1,850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Ocular Therapeutix has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Ocular Therapeutix has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Ocular Therapeutix are expected to decrease in the coming year, from ($0.98) to ($1.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ocular Therapeutix is -5.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ocular Therapeutix is -5.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ocular Therapeutix has a P/B Ratio of 9.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.56% of the float of Ocular Therapeutix has been sold short.

Short Interest Ratio / Days to Cover

Ocular Therapeutix has a short interest ratio ("days to cover") of 8.2.

Change versus previous month

Short interest in Ocular Therapeutix has recently decreased by 7.94%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ocular Therapeutix does not currently pay a dividend.

Dividend Growth

Ocular Therapeutix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -2.01

Percentage of Shares Shorted

8.56% of the float of Ocular Therapeutix has been sold short.

Short Interest Ratio / Days to Cover

Ocular Therapeutix has a short interest ratio ("days to cover") of 8.2.

Change versus previous month

Short interest in Ocular Therapeutix has recently decreased by 7.94%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.99

News Sentiment

Ocular Therapeutix has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Ocular Therapeutix this week, compared to 5 articles on an average week.

Search Interest

7 people have searched for OCUL on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Ocular Therapeutix insiders have sold 111.97% more of their company's stock than they have bought. Specifically, they have bought $69,600.00 in company stock and sold $147,533.00 in company stock.

Percentage Held by Insiders

Only 2.30% of the stock of Ocular Therapeutix is held by insiders.

Percentage Held by Institutions

59.21% of the stock of Ocular Therapeutix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OCUL Stock Analysis - Frequently Asked Questions

How have OCUL shares performed this year?

Ocular Therapeutix's stock was trading at $8.54 at the beginning of 2025. Since then, OCUL shares have decreased by 15.5% and is now trading at $7.22.
View the best growth stocks for 2025 here.

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced its earnings results on Monday, March, 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.05. The biopharmaceutical company earned $17.08 million during the quarter, compared to analysts' expectations of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative trailing twelve-month return on equity of 45.18%.
Read the conference call transcript.

Who are Ocular Therapeutix's major shareholders?

Top institutional shareholders of Ocular Therapeutix include Summer Road LLC (8.71%), Vanguard Group Inc. (5.25%), Adage Capital Partners GP L.L.C. (3.26%) and Deltec Asset Management LLC (1.71%). Insiders that own company stock include Summer Road Llc, Pravin Dugel, Antony C Mattessich, Jeffrey S Heier, Donald Notman, Sanjay Nayak, Richard L Md Lindstrom, Philip C Strassburger, Christopher G White and Rabia Gurses Ozden.
View institutional ownership trends.

How do I buy shares of Ocular Therapeutix?

Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ocular Therapeutix investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Marinus Pharmaceuticals (MRNS) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 3/03/2025
• Today: 5/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OCUL
• CIK: 1393434
• Web: www.ocutx.com
• Phone: (781) 357-4000
• Fax: 781-357-4001
• Employees: 230
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $16.25
• High Stock Price Target: $22.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +125.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-80,740,000.00
• Net Margins: -283.74%
• Pretax Margin: -283.74%
• Return on Equity: -45.18%
• Return on Assets: -30.87%

Debt

• Debt-to-Equity Ratio: 0.19
• Current Ratio: 13.01
• Quick Ratio: 12.94

Sales & Book Value

• Annual Sales: $59.65 million
• Price / Sales: 19.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.79 per share
• Price / Book: 9.14

Miscellaneous

• Outstanding Shares: 159,300,000
• Free Float: 151,714,000
• Market Cap: $1.15 billion
• Optionable: Optionable
• Beta: 1.51